WO2002057424A3 - Nucleic acid delivery formulations - Google Patents

Nucleic acid delivery formulations Download PDF

Info

Publication number
WO2002057424A3
WO2002057424A3 PCT/US2002/001379 US0201379W WO02057424A3 WO 2002057424 A3 WO2002057424 A3 WO 2002057424A3 US 0201379 W US0201379 W US 0201379W WO 02057424 A3 WO02057424 A3 WO 02057424A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
network
controlling
activity
gene expression
Prior art date
Application number
PCT/US2002/001379
Other languages
French (fr)
Other versions
WO2002057424A2 (en
Inventor
Shikha P Barman
Krishnendu Roy
Mary Lynne Hedley
Daqing Wang
Original Assignee
Zycos Inc
Shikha P Barman
Krishnendu Roy
Mary Lynne Hedley
Daqing Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zycos Inc, Shikha P Barman, Krishnendu Roy, Mary Lynne Hedley, Daqing Wang filed Critical Zycos Inc
Priority to JP2002558478A priority Critical patent/JP2004521109A/en
Priority to US10/466,289 priority patent/US20040147466A1/en
Priority to EP02713428A priority patent/EP1352072A4/en
Priority to CA002435287A priority patent/CA2435287A1/en
Publication of WO2002057424A2 publication Critical patent/WO2002057424A2/en
Publication of WO2002057424A3 publication Critical patent/WO2002057424A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

The invention is based on the discovery that injectable and nucleic acid-compatible polymeric compositions and formulations can be structurally designed to regulate nucleic acid activity or gene expression in vivo, for example, by controlling the bioavailability of the nucleic acid via modulation of the biodegradability and crosslink density of the network formed by the components of the formulation. The polymeric network encases the nucleic acid, not only controlling the release of the DNA, but also providing protection from degradation. The invention described herein improves upon prior modes of gene delivery, in that gene expression can be regulated by modulation of a polymeric network formed by combination of at least two water-soluble components capable of reacting with one another. The nucleic acid of interest is incorporated into the network to be released in a sustained manner to achieve level and duration of activity or expression needed.
PCT/US2002/001379 2001-01-17 2002-01-17 Nucleic acid delivery formulations WO2002057424A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002558478A JP2004521109A (en) 2001-01-17 2002-01-17 Formulation for nucleic acid transport
US10/466,289 US20040147466A1 (en) 2002-01-17 2002-01-17 Nucleic acid delivery formulations
EP02713428A EP1352072A4 (en) 2001-01-17 2002-01-17 Nucleic acid delivery formulations
CA002435287A CA2435287A1 (en) 2001-01-17 2002-01-17 Nucleic acid delivery formulations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26221901P 2001-01-17 2001-01-17
US60/262,219 2001-01-17
US27025601P 2001-02-20 2001-02-20
US60/270,256 2001-02-20
US30048401P 2001-06-22 2001-06-22
US60/300,484 2001-06-22

Publications (2)

Publication Number Publication Date
WO2002057424A2 WO2002057424A2 (en) 2002-07-25
WO2002057424A3 true WO2002057424A3 (en) 2002-10-03

Family

ID=27401491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001379 WO2002057424A2 (en) 2001-01-17 2002-01-17 Nucleic acid delivery formulations

Country Status (4)

Country Link
EP (1) EP1352072A4 (en)
JP (1) JP2004521109A (en)
CA (1) CA2435287A1 (en)
WO (1) WO2002057424A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
WO2003070905A2 (en) * 2002-02-15 2003-08-28 Zycos, Inc. Electroporation methods for introducing bioactive agents into cells
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
CN101415443A (en) * 2003-10-23 2009-04-22 阿尔扎公司 Compositions of stabilized DNA for coating microprojctions
US20080095822A1 (en) * 2004-11-16 2008-04-24 Universite De Liege Active Substance Delivery System Comprising A Hydrogel Atrix And Microcarriers
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
WO2012144560A1 (en) * 2011-04-19 2012-10-26 国立大学法人京都大学 Self-gelatinizable nucleic acid
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2016116922A1 (en) * 2015-01-19 2016-07-28 Rappaport Family Institute For Research In The Medical Sciences Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression
KR101637883B1 (en) * 2015-09-30 2016-07-21 선바이오(주) Polyethylene glycol hydrogel injection
KR101666792B1 (en) * 2016-02-05 2016-10-17 주식회사 파마리서치프로덕트 Thermosensitive hydrogel composition containing nucleic acid and chitosan
CN111333878B (en) * 2019-05-23 2020-11-10 吾奇生物医疗科技(镇江)有限公司 Double-crosslinked chitosan hydrogel and preparation method and application thereof
CN109134855B (en) * 2018-07-23 2021-03-23 安徽大学 Acid-sensitive cationic polymer POEAMAM of polyamide amine and preparation method and application thereof
CN113683780B (en) * 2021-09-15 2022-07-05 广州医科大学 Antiserum and low-cytotoxicity polyamino acid gene delivery carrier material with membrane penetrating activity and nucleus positioning function

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412023A (en) * 1989-12-06 1995-05-02 Bollig & Kemper Kg Aqueous dispersions of cross-linked polymer microparticles
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5972707A (en) * 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
US6043094A (en) * 1996-10-11 2000-03-28 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6127499A (en) * 1997-06-30 2000-10-03 Ciba Specialty Chemicals Water Treatments Limited Polymeric materials and their use
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987029B1 (en) * 1998-08-28 2003-01-22 Transgene S.A. Use of a catonic polymer for the preparation of a complex with nucleic acid and related compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412023A (en) * 1989-12-06 1995-05-02 Bollig & Kemper Kg Aqueous dispersions of cross-linked polymer microparticles
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5972707A (en) * 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
US6043094A (en) * 1996-10-11 2000-03-28 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6127499A (en) * 1997-06-30 2000-10-03 Ciba Specialty Chemicals Water Treatments Limited Polymeric materials and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1352072A4 *

Also Published As

Publication number Publication date
EP1352072A2 (en) 2003-10-15
EP1352072A4 (en) 2004-09-01
WO2002057424A2 (en) 2002-07-25
CA2435287A1 (en) 2002-07-25
JP2004521109A (en) 2004-07-15

Similar Documents

Publication Publication Date Title
WO2002057424A3 (en) Nucleic acid delivery formulations
WO2001013891A3 (en) Modulation of release from dry powder formulations
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2002067902A3 (en) Modulation of release from dry powder formulations
WO2008098019A3 (en) Polymer formulations for delivery of bioactive agents
EP0930065A3 (en) Alcohol based anti-microbial compositions with cosmetic appearance
WO2006108009A3 (en) Controlled degradation materials for therapeutic agent delivery
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
NZ527157A (en) Compositions for delivering bisphosphonates
EP1435234A4 (en) Compositions for lessening oxidative stress
WO2001046165A3 (en) N-heteroaryl-amides and their use as parasiticides
HK1103977A1 (en) Stable pegylated interferon formulation
WO2001008717A9 (en) Controlled release implantable devices
WO2005001055A3 (en) Stabilized immunomodulatory oligonucleotides
HRP20010463B1 (en) Controlled release galantamine composition
DE60022664D1 (en) METHOD OF MANUFACTURING SUBMICROMENTIC SUBSTANCES
WO2003000707A3 (en) Antisense modulation of superoxide dismutase 1, soluble expression
WO2006063350A3 (en) Compositions and methods for treating conditions of the nail unit
CA2369444A1 (en) Pharmaceutical compositions of erythropoietin
WO2001004135A3 (en) Crosslinked dna condensate compositions and gene delivery methods
WO2001005355A3 (en) Formulations for il-11
WO2003032947A3 (en) A method for preparing liposome formulations with a predefined release profile
WO2001077080A3 (en) Pyrazole compounds having anti proliferative activity
DE69914934D1 (en) STABLE AQUEOUS INSULIN PREPARATIONS WITHOUT PHENOL AND KRESOL
WO2002015938A8 (en) Testosterone ester formulation for human use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2435287

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002558478

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002713428

Country of ref document: EP

Ref document number: 2002245279

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002713428

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10466289

Country of ref document: US